Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients

References

• International Diabetes Federation. IDF Diabetes Atlas, Seventh Edition. 2015. [cited 2017 Feb 21]. Available from: http://www.diabetesatlas.org/
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2015;38(1):140–149.
   PubMed Web of Science ®Google Scholar
• Japanese Diabetes Society. Evidence-based practice guideline for the treatment for diabetes in Japan 2013. 2013. [cited 2017 May 02]. Available from: http://www.Jds.Or.Jp/modules/en/index.Php?Content_id=44
   Google Scholar
• Patel BD, Ghate MD. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014;74:574–605.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13(2):144–149.
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Wintfeld N, Huang J, et al. The association between nonadherence and glycated hemoglobin among type 2 diabetes patients using basal insulin analogs. Patient Prefer Adherence. 2014;8:873–882.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279–1284.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Promoting health and reducing disparities in populations. Diabetes Care. 2017;40(Suppl 1):S6–S10.
   PubMedGoogle Scholar
• Garcia-Perez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–194.
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical Company Ltd. Zafatek® (trelagliptin succinate) tablet prescribing information (Japanese). 2016. [cited 2017 May 02]. Available from: https://www.takedamed.com/accept/?url=%2Fcontent%2Fmedicine%2Fpdf%2Fzafatek.pdf
   Google Scholar
• McKeage K. Trelagliptin: first global approval. Drugs. 2015;75(10):1161–1164.
   PubMed Web of Science ®Google Scholar
• Grimshaw CE, Jennings A, Kamran R, et al. Trelagliptin (SYR-472, Zafatek), novel once-weekly treatment for type 2 diabetes, inhibits dipeptidyl peptidase-4 (DPP-4) via a non-covalent mechanism. PLoS One. 2016;11(6):e0157509.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Onouchi H, Sano H, et al. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocr. 2014;2(2):125–132.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Onouchi H, Maezawa H, et al. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocr. 2015;3(3):191–197.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Sano H, Seki Y, et al. Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: a 52-week open-label, phase 3 study. J Diabetes Investig. 2016;7(5):718–726.
   PubMed Web of Science ®Google Scholar
• Haque A, Daniel S, Maxwell T, et al. Postmarketing surveillance studies-an industry perspective on changing global requirements and implications. Clin Ther. 2017;39(4):675–685.
   PubMed Web of Science ®Google Scholar
• Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Report on the deliberation results: zafatek (trelagliptin succinate) tablets. 2015. [cited 2017 Jul 28]. Available from: https://www.pmda.go.jp/files/000213963.pdf.
   Google Scholar
• Kaku K. First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2015;16(16):2539–2547.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12(8):648–658.
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical Company Ltd. Drug: trelagliptin succinate. [ cited 2017 Aug 25]. Available from: http://www.genome.jp/dbget-bin/www_bget?dr:D10179.
   Google Scholar
• Salvo F, Moore N, Arnaud M, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. Bmj. 2016;353:i2231.
   PubMed Web of Science ®Google Scholar
• Schnell O, Ryden L, Standl E, et al. Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2016;15(1):139.
   PubMed Web of Science ®Google Scholar
• John M, Gopalakrishnan Unnikrishnan A, Kalra S, et al. Cardiovascular outcome trials for anti-diabetes medication: a holy grail of drug development? Indian Heart J. 2016;68(4):564–571.
   PubMedGoogle Scholar
• Hirshberg B, Katz A. Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care. 2013;36(Suppl 2):S253–258.
   PubMed Web of Science ®Google Scholar
• Japan Pharmaceutical Manufacturers Association. Pharmaceutical administration and regulations in Japan. 2015. [cited 2017 Jul 28]. Available from: http://www.jpma.or.jp/english/parj/pdf/2015.pdf.
   Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• Ida S, Murata K, Betou K, et al. Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study. Cardiovasc Diabetol. 2016;15(1):153.
   PubMed Web of Science ®Google Scholar
• Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol. 2016;8(2):101–109.
   PubMed Web of Science ®Google Scholar
• Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care. 2017;40(2):284–286.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency. Safety measures work. [ cited 2017 Aug 25]. Available from: https://www.pmda.go.jp/safety/index.html.
   Google Scholar
• Attaway A, Mersfelder TL, Vaishnav S, et al. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatol Case Rep. 2014;8(1):24–28.
   PubMedGoogle Scholar
• Aouidad I, Fite C, Marinho E, et al. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol. 2013;149(2):243–245.
   PubMed Web of Science ®Google Scholar
• Béné J, Moulis G, Bennani I, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol. 2016;175(2):296–301.
   PubMed Web of Science ®Google Scholar
• Aoyama H. Drug-related bullous pemphigus occurring in oral patients with DPP-4 inhibitor (Japanese). Dermatological Diagnosis (Japanese). 2016;38(10):964–970.
   Google Scholar
• Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57(5):383–394.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30(2):217–223.
   PubMed Web of Science ®Google Scholar
• Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab. 2012;14(4):348–357.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(9):810–818.
   PubMed Web of Science ®Google Scholar
• Yang HK, Min KW, Park SW, et al. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naive patients with type 2 diabetes. Endocr J. 2015;62(5):449–462.
   PubMed Web of Science ®Google Scholar
• Frederich R, McNeill R, Berglind N, et al. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr. 2012;4(1):36.
   PubMed Web of Science ®Google Scholar
• Yang SJ, Min KW, Gupta SK, et al. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(5):410–416.
   PubMed Web of Science ®Google Scholar
• Sheu WH, Gantz I, Chen M, et al. Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes. Diabetes Care. 2015;38(11):2106–2114.
   PubMed Web of Science ®Google Scholar
• Umezawa S, Kubota A, Maeda H, et al. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: post hoc analysis of the ASSET-K study. BMC Endocr Disord. 2015;15:34.
   PubMed Web of Science ®Google Scholar
• Chen TY, Hsieh CJ. Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus. Postgrad Med. 2014;126(3):205–215.
   PubMed Web of Science ®Google Scholar
• Hsieh CJ, Shen FC. The durability of sitagliptin in elderly patients with type 2 diabetes. Clin Interv Aging. 2014;9:1905–1911.
   PubMed Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696–708.
   PubMed Web of Science ®Google Scholar
• Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig. 2016;7(Suppl 1):102–109.
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Investig. 2014;5(5):475–477.
   PubMed Web of Science ®Google Scholar
• Ayers D, Kanters S, Goldgrub R, et al. Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients. Curr Med Res Opin. 2017;1–9.
   Web of Science ®Google Scholar
• Haneda M, Ito H. Committee Report: glycemic targets for elderly patients with diabetes: Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes. J Diabetes Investig. 2017;8(1):126–128.
   PubMed Web of Science ®Google Scholar
• Halabi A, Maatouk H, Siegler KE, et al. Pharmacokinetics of teneligliptin in subjects with renal impairment. Clin Pharmacol Drug Dev. 2013;2(3):246–254.
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13(10):939–946.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333–337.
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71(11):1441–1467.
   PubMed Web of Science ®Google Scholar
• Rohrborn D, Wronkowitz N, Eckel J. DPP4 in Diabetes. Front Immunol. 2015;6:386.
   PubMed Web of Science ®Google Scholar
• Bando Y, Kanehara H, Aoki K, et al. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients. J Diabetes Investig. 2012;3(2):170–174.
   PubMed Web of Science ®Google Scholar
• Kodera R, Shikata K, Nakamura A, et al. The glucose-lowering efficacy of sitagliptin in obese Japanese patients with Type 2 diabetes. Intern Med. 2017;56(6):605–613.
   PubMed Web of Science ®Google Scholar
• Kubota A, Maeda H, Kanamori A, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig. 2012;3(6):503–509.
   PubMed Web of Science ®Google Scholar